Features include very common findings: Unicameral bone cyst; and common findings: Bone pain, Pathologic fracture, Abnormal humeral diaphysis morphology, and Abnormal proximal femoral metaphysis morphology and others. 17 total HPO annotations.

Biomarker and diagnostic research for solitary bone cyst has been reported in the published literature.

No approved treatments are currently available for solitary bone cyst. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for solitary bone cyst, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for solitary bone cyst. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Phenotype severity distribution: 1 very common feature, 5 common features.

Estimated prevalence: Unknown (Unknown prevalence).

3 clinical trials registered, 2 recruiting. Interventions under study include medical devices and procedural interventions. Pipeline includes 1 PHASE3, 1 NA. Research is primarily sponsored by academic and government institutions.

119 publications have been identified in PubMed for solitary bone cyst. Research spans Case Report / Case Series (54%), Review / Meta-Analysis (25%), and Epidemiology / Natural History (8%).